Abstract

The bankruptcy of 23andMe was an inflection point for the direct-to-consumer genetics market. Although the privacy of consumer data has been highlighted by many as a concern, we discuss another key tension in this case: the corporate enclosure of scientific data that has considerable potential value for biomedical research and public health.

ISSN

1061-4036

DOI

https://doi.org/10.1038/s41588-025-02423-8

Disciplines

Health Law and Policy | Intellectual Property Law | Law | Privacy Law

Share

COinS